BioBalance to begin Probactrix clinical trial for reflux disease

By Elaine Rigoli

Tampa, Fla., Aug. 16 - BioBalance Corp. has started enrollment of a small-scale clinical trial of its proprietary biotherapeutic agent, Probactrix, in the dietary management of patients with gastro-esophageal reflux disease (GERD).

The open-label study will be conducted in about 30 GERD patients to demonstrate the ability of a medical food formulation of Probactrix to improve quality of life in individuals with GERD who are still manifesting symptoms despite ongoing treatment with proton pump inhibitors, the standard medical therapy for the disease, according to a company news release.

New York-based BioBalance is a biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.